Published in Eur Heart J on October 01, 2008
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
[Thromboembolic events in patients after a negative computed tomography pulmonary angiogram: A retrospective study of 165 patients]. Arch Bronconeumol (2006) 2.64
Treatment and blood pressure control in Spain during 2002-2010. J Hypertens (2012) 2.13
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
[PREVENCAT study: control of cardiovascular risk in primary care]. Med Clin (Barc) (2005) 1.76
Short-term clinical outcome after acute symptomatic pulmonary embolism. Thromb Haemost (2008) 1.54
[Prognostic value of electrocardiographic findings in hemodynamically stable patients with acute symptomatic pulmonary embolism]. Rev Esp Cardiol (2008) 1.51
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens (2002) 1.49
Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Prevalence of left-ventricular hypertrophy by multiple electrocardiographic criteria in general population: Hermex study. J Hypertens (2012) 1.45
Evolution of therapy inertia in primary care setting in Spain during 2002-2010. J Hypertens (2014) 1.41
[Ventricular tachycardia in a patient with spongiform myocardiopathy]. Med Clin (Barc) (2004) 1.39
When office blood pressure measurement is not enough. Int J Cardiol (2009) 1.39
Importance of electrocardiographic left ventricular hypertrophy in blood pressure control. J Hypertens (2011) 1.39
Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations. J Hypertens (2014) 1.39
Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study. Rev Esp Cardiol (2011) 1.38
Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med (2005) 1.30
Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax (2010) 1.30
Hypertension and children: should we be aware? Hypertension (2013) 1.10
New blood pressure control goals, more rational but facilitating therapeutic inertia? J Hypertens (2013) 1.09
[Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia]. Rev Esp Cardiol (2004) 1.06
Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr (2007) 0.99
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig (2009) 0.99
The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol (2004) 0.97
Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol (Oxf) (2009) 0.96
Obesity, blood pressure, and cardiovascular outcomes. Lancet (2013) 0.89
Diagnosis of elderly patients with heart failure. Eur J Heart Fail (2012) 0.88
Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer (2004) 0.87
Blood pressure control and physicians' therapeutic behavior in a very elderly Spanish hypertensive population. Hypertens Res (2009) 0.86
Evolution of blood pressure control in Spain. J Hypertens (2007) 0.86
Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag (2008) 0.86
Association of anaemia and mortality in patients with acute pulmonary embolism. Thromb Haemost (2009) 0.86
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens (2007) 0.85
Sudden death after arteriovenous fistula ligation in a renal transplant patient. Ann Vasc Surg (2007) 0.85
[Prognostic value of transthoracic echocardiography in hemodynamically stable patients with acute symptomatic pulmonary embolism]. Arch Bronconeumol (2007) 0.85
Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich) (2007) 0.84
Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. Vasc Health Risk Manag (2008) 0.84
Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther (2008) 0.83
Prognostic significance of delays in diagnosis of pulmonary embolism. Thromb Res (2007) 0.83
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther (2009) 0.83
Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press (2008) 0.81
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials. Adv Ther (2012) 0.80
Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study. Clin Exp Hypertens (2010) 0.80
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail (2010) 0.80
Sex differences in the hypertensive population with chronic ischemic heart disease. J Clin Hypertens (Greenwich) (2008) 0.80
An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. Expert Opin Drug Metab Toxicol (2013) 0.79
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert Opin Pharmacother (2012) 0.79
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother (2008) 0.79
Clinical profile and management of patients with hypertension and chronic ischemic heart disease according to BMI. Obesity (Silver Spring) (2010) 0.79
Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study. J Am Soc Nephrol (2006) 0.79
High heart rate: more than a risk factor. Lessons from a clinical practice survey. Int J Cardiol (2008) 0.79
Diagnosis of heart failure in elderly patients: a clinical challenge. Eur J Heart Fail (2011) 0.79
[Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass]. Arch Bronconeumol (2008) 0.79
Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev (2003) 0.78
[Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension]. Arch Bronconeumol (2010) 0.78
Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst (2006) 0.78
SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. J Investig Allergol Clin Immunol (2011) 0.78
Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol (2010) 0.78
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? Expert Opin Pharmacother (2013) 0.78
Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination? Expert Rev Cardiovasc Ther (2010) 0.78
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther (2013) 0.77
Concomitance of cardiovascular comorbidities in the hypertensive population: not only in the United States. Arch Intern Med (2008) 0.77
Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting. Blood Press (2010) 0.77
Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol (2009) 0.77
Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HEROIC study. J Clin Hypertens (Greenwich) (2010) 0.77
Role of dihydropyridinic calcium channel blockers in the management of hypertension. Expert Rev Cardiovasc Ther (2013) 0.77
Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev Cardiovasc Ther (2008) 0.77
Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels (2010) 0.77
Variables associated with change in blood pressure control status after 1-year follow up in primary care: a retrospective analysis: the TAPAS study. Eur J Prev Cardiol (2013) 0.77
Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens (2006) 0.76
Clinical profile and management of patients with chronic ischemic heart disease according to age in the population daily attended by cardiologists in Spain The ELDERCIC study. Eur J Intern Med (2010) 0.76
Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther (2010) 0.76
Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. Future Cardiol (2014) 0.76
Candesartan in the treatment of hypertension: what have we learnt in the last decade? Expert Opin Drug Saf (2011) 0.76
Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens (2008) 0.76
Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility. Integr Blood Press Control (2010) 0.76
Renal insufficiency should be included in stroke risk scores. Kidney Int (2013) 0.76
[Adequacy of the treatment of hypertensive patients with metabolic syndrome]. Med Clin (Barc) (2007) 0.76
Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension. Expert Opin Pharmacother (2012) 0.76
Diagnostic accuracy of computer-assisted electrocardiography in the diagnosis of left ventricular hypertrophy in left bundle branch block. Rev Esp Cardiol (Engl Ed) (2011) 0.76
Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis (2012) 0.76
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J Renin Angiotensin Aldosterone Syst (2009) 0.76
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) (2008) 0.76
Arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol (2009) 0.75
Renal function and coronary disease: not only in clinical trials. Int J Cardiol (2009) 0.75
Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol (2010) 0.75